ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Feral Mouse Colony Recompetition Given Concept Approval

November 16, 1990

NCI Programs: Seven Win Awards For Cancer Genetics Network, Informatics

July 31, 1998

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

In Brief: Kennedy To Hold Hearing on Mammography Reimbursement, Waxman On Reauthrization

January 15, 1988

Senate Approves $1 Billion For NCI

July 27, 1979

US Could Lose Leadership In Research If NIH Budget Is Cut, ASCO President Says

June 2, 1995